CD200 and acute myeloid leukemia: Here, more than 88% of the patients were classified as MRC‐AML based on only one criterion with respective proportions of 67.2% of AML‐MRC‐C, 17.4% patients with a history of MDS (AML‐MRC‐S) and 15.3% of AML‐MLD‐sole.